Modality
mAb
MOA
BCL-2i
Target
TYK2
Pathway
Angiogenesis
Endometrial Ca
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Dec 2031
ApprovedCurrent
NCT04176905
2,514 pts·Endometrial Ca
2017-06→2025-09·Recruiting
NCT03548491
2,119 pts·Endometrial Ca
2023-04→2031-10·Completed
NCT08873648
857 pts·Endometrial Ca
2023-03→2031-12·Not yet recruiting
+1 more trial
7,640 total pts1 indication
CompletedCurrentUpcoming
Catalysts (4)
2025-09-097mo agoPh3 Readout· Endometrial Ca
2029-02-242.9y awayPh3 Readout· Endometrial Ca
2031-10-205.6y awayPh3 Readout· Endometrial Ca
2031-12-265.7y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Recruit…
Approved
Recruit…
Approved
Not yet…
Approved
Complet…
Catalysts
Ph3 Readout
2025-09-09 · 7mo ago
Endometrial Ca
Ph3 Readout
2029-02-24 · 2.9y away
Endometrial Ca
Ph3 Readout
2031-10-20 · 5.6y away
Endometrial Ca
Ph3 Readout
2031-12-26 · 5.7y away
Endometrial Ca
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04176905 | Approved | Endometrial Ca | Recruiting | 2514 | UPCR |
| NCT03548491 | Approved | Endometrial Ca | Completed | 2119 | Safety |
| NCT08873648 | Approved | Endometrial Ca | Not yet recr... | 857 | 6MWD |
| NCT05203104 | Approved | Endometrial Ca | Recruiting | 2150 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |